Breakthrough Findings from Tongji Hospital's Nationwide Survey

The National Epidemiology Study of Asthma and Allergies in China (NESAAC), spearheaded by researchers from Tongji Hospital affiliated with Tongji University School of Medicine, has delivered the first comprehensive nationwide data on eight major allergic diseases across all age groups. Published on March 6, 2026, in Nature Scientific Reports, this cross-sectional survey involved 121,023 participants from 16 cities spanning seven geographical regions. Conducted between 2010 and 2015 using multistage stratified cluster sampling, it captured urban and rural communities alike through face-to-face interviews with standardized questionnaires. This landmark effort addresses a critical gap, as prior studies often focused on children or specific regions, leaving a fragmented picture of allergy epidemiology in China—a nation grappling with rising allergic burdens amid rapid urbanization and environmental shifts.

Key metrics included lifetime symptoms, current symptoms (past 12 months), and physician-diagnosed cases. The study highlights allergic rhinitis (AR) as the dominant condition at 4.2% current prevalence, underscoring its public health primacy. Asthma followed at 0.9%, with eczema, drug allergy, food allergy, urticaria, contact dermatitis, and anaphylactic shock ranging from 0.7% down to 0.02%. These figures, while seemingly modest, translate to millions affected given China's vast population, amplifying socioeconomic strains through healthcare costs and productivity losses.

Prevalence Breakdown by Disease Type

Allergic rhinitis emerged as the most prevalent, with 4.2% current symptoms, 4.8% lifetime, and 2.3% diagnosed—reflecting underdiagnosis common in chronic nasal issues. Asthma affected 0.9% currently, peaking in older adults. Eczema (0.7%) and urticaria (0.4%) were notable skin manifestations, while food allergy (0.4%) and drug allergy (0.6%) signaled emerging concerns in dietary and pharmaceutical exposures. Contact dermatitis (0.3%) linked to occupational hazards, and rare anaphylactic shock (0.02%) posed acute risks.

Comorbidities amplified impacts: AR co-occurred with asthma in 32.6% of cases, far exceeding other pairs like eczema-AR (20%). This 'united airway disease' concept demands holistic approaches. Lifetime prevalences were higher (e.g., drug allergy 1.8%), suggesting cumulative lifetime burdens. Compared to earlier surveys, like 2008-2018 sensitization shifts, today's data confirm upward trajectories, with AR self-reports climbing from 10-24% in cities.

Regional Disparities: North, East, and South Lead in Prevalence

Marked geographic heterogeneity defined the landscape: North China (e.g., Beijing, Taiyuan) topped lifetime AR at 6.12%, drug allergy 3.72%; East and South followed closely (AR 5.90%, 6.00%). Central (1.95% AR) and Southwest (3.00%) lagged, possibly due to climate, pollution, or lifestyle variances. Urban-rural gaps were stark—AR current symptoms 5.31% urban vs. 2.80% rural—attributed to higher pollutant exposure, Western diets, and hygiene hypothesis failures in cities.

These patterns mirror global trends but intensify in China's megacities, where PM2.5 and aeroallergens exacerbate sensitivities. Northwest and Northeast showed moderate rates (AR lifetime 4.30%, 4.12%), hinting at altitude or dietary protections. For researchers eyeing higher ed research jobs, such data pinpoints hotspots for intervention trials.

Age and Gender Patterns in Allergic Burden

Age stratified risks distinctly: Eczema and food allergies peaked under 6 years, reflecting early sensitizations; AR stabilized post-adolescence; asthma and drug allergies surged after 60, likely from cumulative exposures and immunosenescence. Females outpaced males across most (e.g., diagnosed drug allergy 1.56% vs. 1.01%), possibly hormonal or behavioral factors.

This bimodal distribution—pediatric skin/food, geriatric respiratory—guides age-tailored policies. Projections forecast peaks in allergic nasal disease (AND) up 38,900-56,300 cases amid climate shifts, urging proactive vigilance.

Photo by Markus Winkler on Unsplash

Comorbidities and Unified Disease Management

AR-asthma linkage (32.6% co-prevalence) exemplifies 'one airway, one disease,' with meta-analyses confirming 6.79-14.35% AR-asthma overlap, 26.67-54% vice versa. Eczema-rhinitis (20%) and multi-morbidities in 46.5% of cases strain systems. Integrated care—screening AR in asthmatics—could mitigate. For academic career advice, expertise here opens doors in immunology.

Rising Trends and Risk Factors in Modern China

Prevalences have escalated: AR from 8-14% (2005-2011) to 10-24% urban now; asthma/eczema similarly climbing. Culprits include urbanization (hygiene paradox), pollution, dietary Westernization, climate warming boosting aeroallergens. Family history, urban living amplify risks; rural farm exposures may protect via microbiome diversity. Economic toll: AR/NAR direct/indirect costs vast, with inadequate management exacerbating productivity losses.

Tongji Hospital and University: Pioneering Allergy Research

Tongji Hospital researchers Rongfei Zhu and Nan Huang co-led NESAAC, exemplifying Tongji University's prowess in clinical epidemiology. Affiliated with Huazhong University of Science and Technology, Tongji excels in allergy immunotherapy trials and sensitization studies, impacting global guidelines. This publication bolsters China's research stature, inviting collaborations via university jobs in immunology.

Read the full NESAAC study in Scientific Reports

Public Health Implications and Economic Strain

With millions affected, allergies burden healthcare—AR alone drives frequent visits, absenteeism. Projections signal surges; not yet 'major disease' insured, yet costs rival chronic ills. Targeted screening in high-risk North/East urban females/elderly, allergen control, awareness campaigns essential.

Photo by Markus Winkler on Unsplash

Prevention Strategies and Future Directions

Primary prevention: Early allergen avoidance? Hygiene hypothesis favors exposure. AIT, biologics like omalizumab show promise; TCM adjuncts explored. Policy: Integrate allergies into insurance, pollution mitigation. Future: Longitudinal NESAAC follow-ups, genomics for precision. For postdoc opportunities, allergy hotspots beckon.

Global Context and China's Allergy Challenge

China's 4.2% AR lags Japan's two-thirds total allergies but rises fast vs. West's plateaus. Urban-rural gaps echo developing nations. Tongji's data informs WHO strategies, positioning Chinese academia centrally.

In conclusion, NESAAC illuminates China's allergy epidemiology, urging action. Explore Rate My Professor for allergy experts, higher ed jobs in research, or career advice at AcademicJobs.com.